S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
CAMBRIDGE, Mass.—Attar Eyal C., the Chief Medical (TASE:PMCN) Officer of Vor Biopharma Inc. (NASDAQ:VOR), recently sold 2,227 shares of the company’s common stock. The transaction, which took place on February 13, 2025, was executed at a price of $1.42 per share, amounting to a total value of $3,162. The stock, which has gained over 44% in the past six months according to InvestingPro data, currently trades at $1.43, with analysts setting price targets between $6 and $18.
Following this sale, Eyal holds 126,625 shares in the company. The transaction was conducted under a Rule 10b5-1 trading plan, which had been adopted by Eyal on March 4, 2024. These trading plans allow company insiders to set up a predetermined schedule for buying or selling stock to avoid potential conflicts of interest. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 4.69, though it’s currently experiencing rapid cash burn. Get access to 8 more key ProTips and comprehensive analysis with an InvestingPro subscription.
In other recent news, Vor Biopharma, a biotechnology firm, has made significant adjustments to its stock options. The company’s board of directors approved a reduction of the exercise prices of outstanding stock options for continuous employees to $1.34 per share. This adjustment impacts approximately 6.76 million shares, including options held by executive officers. To benefit from the reduced exercise price, option holders must remain in continuous service with the company until February 3, 2026.
In a continuation of recent developments, Vor Biopharma has also announced the appointment of Erez Kalir to its Board of Directors. Kalir joins the board following a recent private investment in public equity (PIPE) financing led by investor Reid Hoffman. Kalir’s addition is part of Vor Bio’s ongoing efforts to strengthen its leadership as it advances its clinical programs.
Furthermore, Vor Biopharma has secured approximately $55.6 million in gross proceeds from a PIPE deal. The financing, which is expected to close on December 30, 2024, will see Vor Bio issue around 55.9 million shares of common stock along with warrants to purchase approximately 69.8 million shares. The company intends to allocate the net proceeds toward advancing clinical and preclinical development of its pipeline candidates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.